← Back to Screener
Intercure Ltd. Ordinary Shares (INCR)
Price$1.04
Value ScoreA
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-49.27%
Price vs S&P 500 (4W)11.60%
VGM Score75.28
Market Capitalization$60.00M
All Metrics
P/CF (Annual)10.04x
Book Value / Share (Quarterly)$3.48
P/TBV (Annual)3.45x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.83%
Cash Flow / Share (Quarterly)$-0.43
Price vs S&P 500 (YTD)-18.67%
Gross Margin (TTM)31.25%
Net Profit Margin (TTM)-10.09%
EPS (TTM)$-0.44
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-0.44
Revenue Growth (5Y)92.97%
EPS (Annual)$-0.23
ROI (Annual)-6.21%
Gross Margin (Annual)14.90%
Net Profit Margin (5Y Avg)-17.90%
Cash / Share (Quarterly)$0.77
Revenue Growth QoQ (YoY)236.68%
ROA (Last FY)-5.21%
Revenue Growth TTM (YoY)45.15%
EBITD / Share (TTM)$-0.18
ROE (5Y Avg)-5.95%
Operating Margin (TTM)-5.36%
Cash Flow / Share (Annual)$0.09
P/B Ratio0.38x
P/B Ratio (Quarterly)0.46x
Net Income / Employee (Annual)$-39,565
EV / Revenue (TTM)0.46x
Net Interest Coverage (TTM)-1.85x
ROA (TTM)-6.82%
EV / EBITDA (TTM)5.29x
EPS Incl Extra (Annual)$-0.23
Current Ratio (Annual)1.48x
Quick Ratio (Quarterly)1.39x
3-Month Avg Trading Volume0.06M
52-Week Price Return-74.82%
EV / Free Cash Flow (Annual)19.37x
Revenue / Employee (TTM)$620,026
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)0.71x
Asset Turnover (Annual)0.31x
52-Week High$605.00
Operating Margin (5Y Avg)-14.59%
EPS Excl Extra (Annual)$-0.23
CapEx CAGR (5Y)-29.81%
Tangible BV CAGR (5Y)58.48%
26-Week Price Return-34.17%
Quick Ratio (Annual)0.98x
13-Week Price Return8.78%
Total Debt / Equity (Annual)0.46x
Current Ratio (Quarterly)1.85x
Enterprise Value$91.60M
Revenue / Share Growth (5Y)68.43%
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)-7.22%
Revenue / Employee (Annual)$262,500
Inventory Turnover (Annual)1.97x
Pretax Margin (Annual)-36.43%
Cash / Share (Annual)$0.30
3-Month Return Std Dev80.08%
Gross Margin (5Y Avg)35.34%
Net Income / Employee (TTM)$-62,530
ROE (Last FY)-9.07%
Net Interest Coverage (Annual)-0.72x
EPS Basic Excl Extra (Annual)$-0.23
P/FCF (TTM)4.37x
Receivables Turnover (TTM)3.36x
EV / Free Cash Flow (TTM)18.96x
Total Debt / Equity (Quarterly)0.42x
EPS Incl Extra (TTM)$-0.44
Receivables Turnover (Annual)4.20x
ROI (TTM)-8.47%
P/S Ratio (TTM)0.30x
Pretax Margin (5Y Avg)-18.55%
Revenue / Share (Annual)$1.83
Tangible BV / Share (Annual)$0.04
Price vs S&P 500 (52W)-73.60%
Year-to-Date Return-8.67%
5-Day Price Return10.07%
EPS Normalized (Annual)$-0.23
ROA (5Y Avg)-4.04%
Net Profit Margin (Annual)-28.47%
Month-to-Date Return-17.83%
Cash Flow / Share (TTM)$0.18
EBITD / Share (Annual)$-0.12
Operating Margin (Annual)-28.05%
LT Debt / Equity (Annual)0.20x
ROI (5Y Avg)-4.77%
LT Debt / Equity (Quarterly)0.18x
EPS Basic Excl Extra (TTM)$-0.44
P/TBV (Quarterly)1.18x
P/B Ratio (Annual)0.49x
Inventory Turnover (TTM)3.45x
Pretax Margin (TTM)-10.43%
Book Value / Share (Annual)$2.54
Price vs S&P 500 (13W)-1.80%
Beta0.61x
P/FCF (Annual)12.68x
Revenue / Share (TTM)$4.31
ROE (TTM)-11.64%
52-Week Low$225.30
vGradeA
gGradeA
mGradeC
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INCRIntercure Ltd. Ordinary Shares | A | A | C | $1.04 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Intercure Ltd cultivates and produces pharmaceutical-grade cannabis products in dried flower and oil forms for the medical market. The company operates through two business segments: direct cannabis production and biomedical portfolio investments, with the majority of revenue derived from its cannabis operations.